underscored material = new [bracketed material] = delete 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1 51 .195503.1 possible withinthe specificchemicaldesignation: existence oftheseisomers,esters, ethers andsaltsis and ethers,unlessspecificallyexempted, wheneverthe isomers, esters,ethers,salts,and salts ofisomers,esters substances areincludedinSchedule I: Chapter 84,Section6,asamended)isamendedtoread: BE ITENACTEDBYTHELEGISLATUREOFSTATENEWMEXICO: SUBSTANCES TOTHELISTOFSCHEDULEICONTROLLEDSUBSTANCES. SUBSTANCES ACTTOADDMORESYNTHETICCANNABINOIDSANDOTHER RELATING TOCONTROLLEDSUBSTANCES;AMENDINGTHE ST LEGISLATURE "30-31-6. SCHEDULEI.--Thefollowingcontrolled SECTION 1. A. anyofthefollowingopiates,including their Section30-31-6NMSA1978(beingLaws1972, - (1) acetylmethadol;

STATE Sue WilsonBeffort

OF SENATE BILL127 INTRODUCED BY

NEW AN ACT

MEXICO

- SECONDSESSION ,

2014 underscored material = new [bracketed material] = delete 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1 .195503.1 (6) alph-methy1fentany1; (5) alphamethadol; (4) alphameprodine; (3) alphacetylmethadol; (2) allylprodine; [(16) [(6) [(24) [(23) [(22) [(21) [(20) [(19) [(18) [(17) (17) difenoxin; [(15) [(14) [(13) [(12) [(11) [(10) [(9) [(8) [(7) ] (10) ] (9) ] (8) ] (7) ] (20) ] (19) ] (18) ] (16) ] (15) ] (14) ] (13) ] (12) ] (11) ] (26) ] (25) ] (24) ] (23) ] (22) ] (21) betameprodine; betacetylmethadol; benzethidine; betamethadol; furethidine; etoxeridine; ; ethylmethylthiambutene; dipipanone; dioxaphetylbutyrate; dimethylthiambutene; dimepheptanol; dimenoxadol; diethylthiambutene; diampromide; ; dextromoramide; clonitazene; betaprodine; - 2 underscored material = new [bracketed material] = delete 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1 .195503.1 designation: salts ofisomersispossiblewithin the specificchemical exempted, whenevertheexistenceof these salts,isomersand salts, isomersandsaltsofisomers, unlessspecifically B. anyofthefollowingopiumderivatives, their [(25) (44) tilidine;and [(42) [(34) [(33) [(32) [(31) [(30) [(29) [(28) [(27) [(26) (1) acetorphine; [(41) [(40) [(39) [(38) [(37) [(36) [(34) ] (45) ] (43) ] (42) ] (41) ] (40) ] (39) ] (38) ] (37) ] (36) ] (35) ] (34) ] (33) ] (32) ] (31) ] (30) ] (29) ] (28) ] (27) norpipanone; normethadone; norlevorphanol; noracymethadol; morpheridine; levophenacylmorphan; levomoramide; ; hydroxypethidine; trimeperidine; racemoramide;[and properidine; proheptazine; piritramide; phenoperidine; phenomorphan; phenampromide; phenadoxone; - 3 ] underscored material = new [bracketed material] = delete 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1 .195503.1 (9) dehydromorphine; (8) dihydromorphine; (7) desomorphine; (6) ; (5) codeine-N-oxide; (4) codeinemethylbromide; (3) benzylmorphine; (2) acetyldihydrocodeine; [(9) (26) 3-methylthiofentanyl; (25) beta-hydroxy-3-methylfentanyl; (22) [(21) [(20) [(19) [(18) [(17) [(16) [(15) [(14) [(13) [(12) [(11) [(10) (24) drotebanol; ] (23) ] (10) ] (20) ] (19) ] (18) ] (17) ] (16) ] (15) ] (14) ] (13) ] (12) ] (11) ] (22) ] (21) etorphine; thebacon; pholcodine;[and normorphine; nicomorphine; nicocodeine; myrophine; -N-oxide; morphinemethylsulfonate; morphinemethylbromide; methyldihydromorphine; methyldesorphine; hydromorphinol; ; - 4 underscored material = new [bracketed material] = delete 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1 .195503.1 the ControlledSubstances Act; chemical designation: isomers andsaltsofispossiblewithinthespecific specifically exempted,whenevertheexistenceofthesesalts, substances, theirsalts,isomersandsaltsofisomers,unless that containsanyquantityofthefollowinghallucinogenic or (STP) ; C. anymaterial,compound,mixtureorpreparation (27) acetyl--methylfentanyl; (12) peyote,except asotherwiseprovidedin (11) ; (10) marijuana; (9) lysergicaciddiethylamide; (8) ; (7) 4-methyl-2,5-dimethoxy-(DOM) (31) thiofentanyl; (30) para-fluorofentanyl;and (29) beta-hydroxfentanyl; (28) alpha-methylthiofentanyl; (6) dimethyltryptamine(DMT) (5) (DET) (4) bufotenine; (3) 3,4,5-; (2) 5-methoxy-3,4-methylenedioxyamphetamine; (1) 3,4-methylenedioxyamphetamine; - 5 ; ; underscored material = new [bracketed material] = delete 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1 .195503.1 propylthiophenethylamine (-T-7); or (TPCP); pyrrolidine (PCPy),(PHP)analogofthedrugphencyclidine; phenylcyclohexylamine (PCE); 2, 5-DMA; ); delta-9-tetra-hydrocannabinol (THC),anactiveingredientof [(19) syntheticcannabinoids,including (18) hashish; (17) ; (16) psilocyn; (15) ; (14) N-methyl-3-piperidylbenzilate; (13) N-ethyl-3-piperidylbenzilate; (25) thiophene(analogofphencyclidine) (TCP) (24) pyrrolidine1-(1-phenylcyclohexyl)- (23) ethylamineN-ethyl-1- (22) 4-methoxyamphetamine;PMA; (21) 4-bromo-2,5-dimethoxy-amphetamine; (20) 2,5-dimethoxyamphetamine;2,5-DMA; (29) 2,.5dimethoxy-4-(n)- (28) ibogaine; (27) 2,5-dimethoxy-4-ethylamphet-amine; (26) alpha-ethyltryptamine; (19) (syntheticanalogof - 6 ] underscored material = new [bracketed material] = delete 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1 (5-MeO-DIPT); .195503.1 pentylindol-3-yl)methanone; chlorophenylacetyl)indole); 10,10a-tetrahydro -6,6,9-trimethyl-6H dibenzo[b,d]pyran; naphthoyl)indole); methoxynaphthoy)]indole); hydroxypropyl) cyclohexyl]-5-(2-methyloctan-2-yl)phenol); decahydronaphthalen-2-ol); hydroxy-4-(2-methyloctan-2-yl)phenyl] 1,2,3,4,4a,5,6,7,8,8a- analogs orhomologswithbindingactivity,including: demonstrate bindingactivitytothecannabinoidreceptoror contains anyquantityofsyntheticcannabinoidsthat including anymaterial,compound,mixtureorpreparationthat specifically exemptedorunlesslistedinanotherschedule, (30) alpha-methyltryptamine(AMT); (32) syntheticcannabinoids,unless (31) 5-methoxy-N,N- (e) JWH-1333-(1,1-dimethylbutyl)-6a,7, (d) JWH-122(1-pentyl-3-(4-methyl-1- (c) JWH-081(1-pentyl-3-[1-(4- (b) CP55,940(5-hydroxy-2-(3- (a) CP55,244((hydroxymethyl)-4-[2- (h) AM-694(1-(5-fluoropentyl)-3-(2- (g) JWH2104-ethylnaphthalen-1-yl-(1- (f) JWH2031-pentyl-3-(2- - 7 underscored material = new [bracketed material] = delete 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1 methyl-2-methyl-3-(1-naphthoyl)-6-nitroindole; .195503.1 alkenyl, cycloalkylmethyl, cycloalkylethyl, at thenitrogenatom oftheindoleringbyanalkyl, haloalkyl, containing a3-(1-naphthoyl)indole structure withsubstitution chemical designation:1)naphthoylindoles, oranycompound isomers andsaltsofispossible withinthespecific specifically excepted,wheneverthe existence ofthesesalts, , theirsalts,isomersand saltsofisomers,unless naphthalenylmethanone); 3-(4-morpholinylmethyl)pyrrolo-1,4-benzooxazin6-yl)-1- methanone; methoxyphenyl)-[2-methyl-1-(2-morpholin-4-ylethyl)indol-3-yl] ethylnaphthoyl)indole); (2-methoxyphenylacetyl)indole); methoxy)-benzoyl]indole); naphthoyl)indole); iodobenzoyl)indole); (p) anyofthefollowingsynthetic (o) WIN-55,212-2(2,3-dihydro-5-methyl- (n) WIN-49,098()(4- (m) JWH-210(1-pentyl-3-(4- (l) RCS-8orSR-18(1-cyclohexylethyl-3- (k) RCS-4orSR-19(1-pentyl-3-[(4- (j) AM-2201(1-(5-fluoropentyl)-3-(1- (i) AM-1221(1-(N-methylpiperdin-2-yl) - 8 underscored material = new [bracketed material] = delete 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1 to anyextent,including,butnotlimitedto,JWH-015,JWH-018, any extent,andwhetherornotsubstitutedinthenaphthylring group, whetherornotfurthersubstitutedintheindoleringto .195503.1 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) 3-position ofthe indene ringbyanalkyl,haloalkyl, alkenyl, naphthylideneindene structurewithsubstitution atthe naphthylmethylindenes, oranycompound containinga extent, including,butnotlimitedto, JWH-307;4) and whetherornotsubstitutedinthe naphthylringtoany or notfurthersubstitutedinthepyrrole ringtoanyextent, piperidinyl) methylor2-(4-morpholinyl)ethylgroup,whether alkenyl, cycloalkylmethyl,cycloalkylethyl,1-(N-methyl-2- nitrogen atomofthepyrroleringbyanalkyl,haloalkyl, 3-(1-naphthoyl) pyrrolestructurewithsubstitutionatthe and JWH-199;3)naphthoylpyrroles,oranycompoundcontaininga to anyextent,including,butnotlimitedto,JWH-175,JWH-184 any extent,andwhetherornotsubstitutedinthenaphthylring group, whetherornotfurthersubstitutedintheindoleringto 1-(N-methyl-2-piperidinyl) methylor2-(4-morpholinyl)ethyl alkyl, haloalkyl,alkenyl,cycloalkylmethyl,cycloalkylethyl, substitution atthenitrogenatomofindoleringbyan containing a1hindol-3-yl-(1-naphthyl)methanestructurewith and AM-2201;2)naphthylmethylindoles,oranycompound JWH-019, JWH-073,JWH-081,JWH-122,JWH-200,JWH-210,JWH-398 1-(N-methyl-2-piperidinyl) methylor2-(4-morpholinyl)ethyl - 9 underscored material = new [bracketed material] = delete 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1 but notlimitedto,JWH-176;5)phenylacetylindoles,orany not substitutedinthenaphthylringtoanyextent,including, substituted intheindeneringtoanyextent,andwhetheror .195503.1 substituted inthe indoleringtoanyextent,andwhether or methyl or2-(4-morpholinyl) ethylgroup,whetherornot further cycloalkylmethyl, cycloalkylethyl,1-(N-methyl-2-piperidinyl) atom oftheindoleringbyanalkyl, haloalkyl,alkenyl, OTS-3833.4 indolestructurewithsubstitution atthenitrogen benzoylindoles, oranycompoundcontaining a3-(benzoyl)[5] 47,497 C8homologue),CPand CP 55,490;and7) extent, including,butnotlimitedto,(CP group, whetherornotsubstitutedinthecyclohexylringtoany 1-(N-methyl-2-piperidinyl) methylor2-(4-morpholinyl)ethyl alkyl, haloalkyl,alkenyl,cycloalkylmethyl,cycloalkylethyl, substitution atthe5-positionofphenolicringbyan containing a2-(3-hydroxycyclohexyl)phenolstructurewith JWH-251 andRCS-8;6)cyclohexylphenols,oranycompound to anyextent,including,butnotlimitedto,JWH-203,JWH-250, any extent,andwhetherornotsubstitutedinthephenylring group, whetherornotfurthersubstitutedintheindoleringto 1-(N-methyl-2-piperidinyl) methylor2-(4-morpholinyl)ethyl alkyl, haloalkyl,alkenyl,cycloalkylmethyl,cycloalkylethyl, substitution atthenitrogenatomofindoleringbyan compound containinga3-phenylacetylindolestructurewith methyl or2-(4-morpholinyl)ethylgroup,whethernotfurther - 10 underscored material = new [bracketed material] = delete 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1 .195503.1 10a-tetrahydrobenzo[c]chromen-1-ol); -6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10, 1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol; -3-hydroxycyclohexyl]-phenol (CP-47,497); and5-(1, 497 andhomologues:5-(1,1-dimethylheptyl)-2-[(1R,3S) methoxyphenylacetyl) indole; indole; -3-(1-naphthoyl)indole; AM-1241; but notlimitedto,AM-694,pravadoline(WIN48,098),RCS-4and indazole-3-carboxamide; 3-yl(2,2,3,3-tetramethylcyclopropyl)methanone; 3,3-tetramethylcyclopropyl)methanone; not substitutedinthephenylringtoanyextent,including, [(a) (s) AKB48N-(1-adamantyl)-1-pentyl-1H- (r) XLR111-(5-fluoro-pentyl)-1H-indol- (q) UR-1441-(pentyl-1H-indol-3-yl)(2,2, [(d) [(c) [(h) [(g) [(f) [(e) [(b) ] (aa) ] (z) ] (y) ] (x) ] (w) ] (v) ] (u) ] (t) - 11 6aR,10aR)-9-(hydroxymethyl) cannabicyclohexanol(CP47, 1-pentyl-3-(2- 1-pentyl-3-(1-naphthoyl) 1-hexyl-3-(1-naphthoyl)indole; 1-butyl-3-(1-napthoyl)indole; 1-[2-(4-(morpholinyl)ethyl] ,(6aS,10aS) underscored material = new [bracketed material] = delete 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1 hydroxy cyclohexyl)-phenol; 3-yl)-1-naphthalenyl-methanone; and naphthoyl) indole; .195503.1 -dioxododecahydro-2H-benzo[f]isochromene-7-carboxylate); 9S,10aS,10bR)-9-(acetyloxy)-2-(furan-3-yl)-6a,10b-dimethyl-4,10 liability, including: of thesubstancetoproducepsychicorphysiologicaldependence the publichealthbyabuseofsubstanceandpotential have thepharmacologicaleffectofsubstance,riskto -6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol; -9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl) (25) (41) 4-ethyl-methcathinone (4-EMC); (40) 4-methyl-ethylcathinone (4-MEC); [(20) [(21) [(24) [(23) [(22) (39) substancesdeterminedbytheboardto ] (38) ] (37) ] (36) ] (35) ] (34) ] (33) (b) salvinorinA(methyl(2S,4aR,6aR,7R, (a) salviadivinorum;and [(k) [(j) [(i) ] (dd) ] (cc) ] (bb) 4-fluoromethcathinone; 3,4-methylenedioxymethcathinone; 3-fluoromethcathinone;[and 4-methoxymethcathinone; 4-methylmethcathinone; 3,4-methylenedioxypyrovalerone; - 12 5-(1,1-dimethylheptyl)-2-(3- (2-methyl-1-propyl-1H-indol- 1-pentyl-3-(4-chloro underscored material = new [bracketed material] = delete 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1 (); (ethcathinone); .195503.1 (alpha-PVP); (MPBP); pyrrolidinobutiophenone (MDPBP); pyrrolidinopropiophenone (MDPPP); (MPPP); (MOPPP); (alpha-PPP); benzodioxyolybutanamine (bk-MBDB,); (42) 2-ethylamino-1-phenyl-propan-1-one (52) 3',4'-methylenedioxy-alpha- (51) 3',4'-methylenedioxy-alpha- (50) 4'-methyl-?-pyrrolidinopropiophenone (49) 4'-methoxy-alpha-pyrrolidinopropiophenone (48) alpha-pyrrolidinobutiophenone(?-PBP); (47) alpha-pyrrolidinopropiophenone (46) N,N-dimethylcathinone(metamfepramone); (45) naphthylpyrovalerone(NRG-1,naphyrone); (44) beta-keto-N-methyl-3,4- (43) 3',4'-methylenedioxyethcathinone (56) alpha-methylamino-butyrophenone (55) 5,6-methylenedioxy-2-aminoindane (MDAI); (54) alpha-pyrrolidinovalerophenone (53) 4'-methyl-?-pyrrolidinobutiophenone - 13 underscored material = new [bracketed material] = delete 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1 (eutylone); and .195503.1 designation: salts ofisomersispossiblewithinthespecificchemical of isomers,whenevertheexistencesuchsalts,isomersand central nervoussystem,includingitssalts,isomersandsalts the followingsubstanceshavingadepressanteffecton compound, mixtureorpreparationthatcontainsanyquantityof or unlesslistedinanotherschedule,includinganymaterial, (pentylone); (buphedrone); D. anyofthefollowing,unlessspecificallyexempt (3) benzodiazepines,including: (2) methaqualone; (1) mecloqualone; (58) beta-keto-ethylbenzodioxolylpentanamine (57) beta-keto-ethylbenzodioxolylbutanamine (c) cloxazolam; (b) camazepam; (a) bromazepam; (i) ketazolam; (h) haloxazolam; (g) flunitrazepam; (f) fludiazepam; (e) ethylloflazepate; (d) delorazepam; - 14 underscored material = new [bracketed material] = delete 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1 .195503.1 salts ofisomers: on thecentralnervoussystem,including itssalts,isomersand quantity ofthefollowingsubstances havingastimulanteffect material, compound,mixtureorpreparationthatcontainsany exempted orunlesslistedinanotherschedule,includingany that ismetabolicallyconvertedtoGHB; compound thatismetabolicallyconvertedtoGHB;and compound thatismetabolicallyconvertedtoGHB; E. anyofthefollowing,unlessspecifically (6) 1-4butanediolandanychemicalcompound (5) gammabutyrolactoneandanychemical (4) gammahydroxybutyricacidandanychemical (4) N,N-dimethylamphetamine; and (3) cis-4-methylaminorex; (2) N-ethylamphetamine; (1) fenethylline; (j) loprazolam; (r) tetrazepam; (q) pinazepam;and (p) oxazolam; (o) nordiazepam; (n) nitrazepam; (m) nimetazepam; (l) medazepam; (k) lormetazepam; - 15 underscored material = new [bracketed material] = delete 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1 that containsanyquantityofthefollowingsubstances: ); salts ofisomers; piperidine (PEPAP),includingitsopticalisomers,saltsand isomers; (MPPP), includingitsopticalisomers,salts,andsaltsof and saltsofisomers; including itsoptical,positionalandgeometricisomers,salts and geometricisomers,saltsofisomers; ethyl)-4-piperidyl)-N-phenylpropanamide, includingitsoptical .195503.1 comply withthefederal ComprehensiveDrugAbusePrevention and distributes peyote totheorganizationoritsmembers shall registration. Anypersonwhomanufactures peyoteforor members oftheorganizationsousing peyoteareexemptfrom religious ceremoniesbyabonafide religious organization,and substance doesnotapplytotheuse of peyoteinbonafide [D. F. anymaterial,compound,mixtureorpreparation ] G. (5) N-benzylpiperazine(BZP,1- (6) methcathinone; (5) cathinone;and (4) 1-(-2-phenylethyl)-4-phenyl-4-acetoxy (3) 1-methyl-4-phenyl-4-proprionoxypiperidine (2) 3,4-methylenedioxymethamphetamine(MDMA), (1) 3-methylfentanyl(N-3-methyl-1-(2-phenyl- theenumerationofpeyoteasacontrolled - 16 underscored material = new [bracketed material] = delete 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1 Control Actof1970andallotherrequirementslaw; 1978." by ruleadoptedtheboardpursuanttoSection30-31-3NMSA provisions oftheLynnandErinCompassionateUseAct; Research Actorbyqualifiedpatientspursuanttothe patients pursuanttotheControlledSubstancesTherapeutic chemical derivativesoftetrahydrocannabinolbycertified not applytotheuseofmarijuana,tetrahydrocannabinolsor asScheduleIcontrolledsubstancesdoes tetrahydrocannabinols orchemicalderivativesof .195503.1 [E. [F. ] I. ] H. controlledsubstancesaddedtoScheduleI theenumerationofmarijuana, - 17